Insiders Trades
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (6 ops.)
Latest filing published 15 Sept 2026 for CYTOKINETICS INC, €62k. Read the official filing
Filing timeline
BuySaleRobert E. Landry
Insider track record
Disclosed buys
0
Disclosed sells
6
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Robert E. Landry: trading record in brief
Robert E. Landry is a declared insider at 2 companies (finance chief); the most frequent names are Regeneron Pharmaceuticals, Inc. and Cytokinetics Inc. Between 6 August 2021 and 15 September 2026, the trades on record add up to 32 filings.
The open-market record consists of 6 sales worth €1.2M, with no purchase. The rest of the record consists of 6 share grants and 20 option exercises. So far in 2026, the count stands at no purchases and 2 sales.
On 15 September 2026 came the latest disclosure, an open-market sale for €62k in Cytokinetics Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Robert E. Landry
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations32 total
1,000 shares@ US$72.13Common StockSEC:0001061983-26-000095:0
1,000 shares@ US$74.660.0008% mcap100.0% of flowCommon StockSEC:0001061983-26-000093:0
2,851 shares0Common StockSEC:0001061983-26-000056:0
7,333 shares0Common StockSEC:0001127602-25-014356:0
400 shares@ US$378.980.7% of flowCommon StockSEC:0001968202-24-000053:0
400 shares@ US$378.980.7% of flowCommon StockSEC:0001968202-24-000045:0
1,100 shares@ US$378.981.9% of flowCommon StockSEC:0001968202-24-000040:0
500 shares@ US$378.980.9% of flowCommon StockSEC:0001968202-24-000036:0
800 shares@ US$378.981.4% of flowCommon StockSEC:0001968202-24-000034:0
500 shares@ US$378.980.8% of flowCommon StockSEC:0001968202-24-000031:0
650 shares@ US$378.981.1% of flowCommon StockSEC:0001883850-24-000005:0
750 shares@ US$378.981.3% of flowCommon StockSEC:0001883850-23-000108:0
6,381 shares@ US$856.7124.9% of flowCommon StockSEC:0001883850-23-000100:0
1,013 shares@ US$843.793.9% of flowCommon StockSEC:0001968202-23-000051:0
223 shares@ US$844.000.8% of flowCommon StockSEC:0001968202-23-000030:0
800 shares@ US$381.921.4% of flowCommon StockSEC:0001968202-23-000004:0
739 shares@ US$764.502.5% of flowCommon StockSEC:0001883850-23-000035:0
3,853 shares0Common StockSEC:0001883850-22-000132:0
3,000 shares@ US$381.925.3% of flowCommon StockSEC:0001883850-22-000107:0
2,500 shares@ US$381.924.5% of flowCommon StockSEC:0001883850-22-000102:0
2,000 shares@ US$381.923.8% of flowCommon StockSEC:0001883850-22-000086:0
1,500 shares@ US$381.922.9% of flowCommon StockSEC:0001883850-22-000082:0
1,500 shares@ US$399.663.2% of flowCommon StockSEC:0001883850-22-000040:0
1,500 shares@ US$399.663.1% of flowCommon StockSEC:0001883850-22-000028:0
1,250 shares@ US$555.673.7% of flowCommon StockSEC:0001883850-22-000022:0
25 of 32 declarations
